AKTS — Aktis Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2035832 ·
Last close
$20.58
Market Cap
$1.10B
52W High
$23.05
52W Low
$14.72
ADV30
193,621
Next earnings
2026-05-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,227,000 | — | -22,706,000 | -18,325,000 | 576,801,000 | 371,630,000 | 70,693,000 |
| Dec 2025 | 1,870,000 | — | -17,375,000 | -15,138,000 | 264,885,000 | 37,784,000 | 411,034,000 |
| Sep 2025 | — | — | — | — | 279,037,000 | 180,253,000 | 411,430,000 |
| Mar 2025 | 1,447,000 | — | -18,143,000 | -14,985,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,040,000
Investing CF
$-299,338,000
Financing CF
$-2,576,000
CapEx
$-6,383,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-156,564,000
Inventory
—
Receivables
—
ST Investments
$189,003,000
EBIT TTM
$-33,010,000
Pretax Income TTM
$-27,194,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,277,000
EBITDA
$-76,750,000
Free Cash Flow
—
Enterprise Value
$597,436,288
Total Cash
$538,483,968
Total Debt
$11,577,000
Shares Out
53,404,618
Trailing EPS
$-1.21
Book Value
$9.16
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,497,000 | -74,684,000 | -63,731,000 | 264,885,000 | 411,034,000 | — | -64,127,000 |
| Dec 2024 | 1,487,000 | -52,050,000 | -43,980,000 | 326,181,000 | 413,984,000 | — | 14,762,000 |
| Dec 2023 | 0 | -34,794,000 | -28,641,000 | 122,355,000 | 168,661,000 | — | -30,004,000 |
| Dec 2022 | 0 | -19,764,000 | -17,929,000 | 138,322,000 | 157,552,000 | — | -18,125,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.96
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.10B | $33.78 | — |
| MNKD | MANNKIND CORP | $1.09B | $3.53 | — |
| IVEVF | Inventiva S.A. | $1.11B | $5.33 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.08B | $6.26 | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.08B | $12.83 | — |
News headlines (Yahoo Finance, 1h cache)
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
2026-05-25 19:05 · Yahoo
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
2026-05-21 21:21 · Yahoo
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
2026-05-13 20:30 · Yahoo
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
2026-05-11 20:01 · Yahoo
Aktis Oncology to Present at the BofA Securities Health Care Conference
2026-05-06 12:00 · Yahoo
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
2026-05-05 14:14 · Yahoo
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2026-05-04 20:05 · Yahoo
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump
2026-04-26 13:04 · Yahoo
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2026-04-21 21:00 · Yahoo
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
2026-04-17 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.